Join Us At The European Respiratory Society Congress
8-10 September, 2024
Do you offer all optionsāØto reduce breathlessnessāØfor severe COPD/emphysema?
Come visit our booth #A 1.08āØto learn more on ZephyrĀ® ValvesāØas a proven treatment.
Find Us
Visit us at booth #A1.08 to experience our evidence-based therapeutic solution for severe COPD/emphysema and discuss patient selection and assessment.
Meet Us
Helping Patients Breathe Easier, Do More & Enjoy LifeĀ¹
ZephyrĀ Valves are a proven treatment for breathlessness from severe COPD/emphysema
Zephyr Valves in a Nutshell
The Zephyr Valve is a clinically-proven bronchoscopic treatment for patients with severe COPD/emphysema.
Ā¹Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151ā1164
Ā²Hartman JE, Welling JBA et. al. Respir Med. 2022; doi:10.1016/j.rmed.2022.106825; Single-center retrospective study of 1471 COPD patients referred for BLVR.
483 patients undergoing bronchoscopic lung volume reduction compared to patients who were not eligible for BLVR (n=988).
Sessions of Interest
The Zephyr Valve is a standard of care treatment option. Check out the presentations during ERS 2024, highlighting endobronchial valves (EBV) as a treatment option.
Plenary session
Imaging for selection of COPD patients for lung volume reduction
D. Slebos
Groningen, Netherlands
Sept 8, 2024 – 13:45 ā 15:15
Room: C1 (Live-Streamed)
Poster session
Five-year durability of Zephyr Valves in patients with severe emphysema
G. Criner
Philadelphia, United States
Sept 9, 2024 – 08:00 – 09:30
Room: PS-1
Oral presentation
Lobar volume reduction of ā„ 50% with Zephyr Valves correlates with significant reduction in longer-term rate of severe COPD exacerbations
M. Dransfield
Birmingham, United States
Sept 9, 2024 – 09:30 ā 10:45
Room: Strauss 2
Oral presentation
Zephyr Valves benefits previously ineligible patients after blocking of collateral channels with AeriSeal: CONVERT Trial
K. Darwiche
Essen, Germany
Sept 9, 2024 – 09:30 ā 10:45
Room: Strauss 2
Oral presentation
Impact of endobronchial valve treatment for COPD with or without pulmonary rehabilitation on symptoms of fatigue, anxiety and depression ā the SoLVE Study
R. Posthuma
Maastricht, Netherlands
Sept 9, 2024 – 09:30 – 10:45
Room: Strauss 2
Watch testimonials from healthcare professionals on EBV as a part of standard of care treatment option and learn about evidence recommending valves as a treatment for severe COPD/emphysema patients.
Quiz
Take the opportunity to test your knowledge on endobronchial valves for severe COPD/emphysema patients
EUR-EN-2351-v1
